Treatment with ERRγ inverse agonist, DN200434, increased mitochondrial ROS production and decreased mTOR activity and GPX4 levels in HCC cells by decreasing GSH/GSH disulfide levels, which, in turn, increased ferroptosis and their sensitivity to sorafenib.[91]. The gene discussed is GPX4; the disease is hepatocellular carcinoma.